INMB Stock Overview A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
INmune Bio, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for INmune Bio Historical stock prices Current Share Price US$4.49 52 Week High US$14.74 52 Week Low US$4.32 Beta 1.78 1 Month Change -7.99% 3 Month Change -13.98% 1 Year Change -60.79% 3 Year Change -56.58% 5 Year Change -27.03% Change since IPO -43.80%
Recent News & Updates
New minor risk - Market cap size Dec 20
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease Nov 13
New major risk - Revenue and earnings growth Nov 07
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? Nov 03
Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) Nov 01
INmune Bio, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 24 See more updates
New minor risk - Market cap size Dec 20
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease Nov 13
New major risk - Revenue and earnings growth Nov 07
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? Nov 03
Third quarter 2024 earnings released: US$0.60 loss per share (vs US$0.48 loss in 3Q 2023) Nov 01
INmune Bio, Inc. to Report Q3, 2024 Results on Oct 31, 2024 Oct 24
CFO, Treasurer & Secretary recently bought US$53k worth of stock Oct 01
INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease Oct 01
INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal Sep 30
Co-Founder recently bought US$98k worth of stock Sep 18
INmune Bio, Inc. Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints Sep 17 INmune Bio, Inc. has filed a Follow-on Equity Offering. Sep 14
INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $75 million. Aug 10
Consensus EPS estimates upgraded to US$2.26 loss Aug 08
New minor risk - Profitability Aug 04
Second quarter 2024 earnings released: US$0.51 loss per share (vs US$0.36 loss in 2Q 2023) Aug 02
INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™? on Proteins That Regulation Synapse in Alzheimer's Patients Jul 29
INmune Bio, Inc. to Report Q2, 2024 Results on Aug 01, 2024 Jul 25
It's Unlikely That Shareholders Will Increase INmune Bio, Inc.'s (NASDAQ:INMB) Compensation By Much This Year Jul 12
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer's Disease Trial Jun 28
INmune Bio, Inc., Annual General Meeting, Jul 19, 2024 May 31
New major risk - Revenue and earnings growth May 13
Full year 2023 earnings released: US$1.67 loss per share (vs US$1.52 loss in FY 2022) May 12
Consensus EPS estimates fall by 24% May 12
INmune Bio, Inc. to Report Q1, 2024 Results on May 09, 2024 May 09 INmune Bio, Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial INmune Bio, Inc. has filed a Follow-on Equity Offering in the amount of $9.70224 million. Apr 26
Independent Director recently bought US$246k worth of stock Apr 25
Inmune Bio Inc. Announces 24-Month Stability Validation of Xpro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay Apr 25 INmune Bio, Inc. has filed a Follow-on Equity Offering. Apr 23
Consensus revenue estimates decrease by 35%, EPS upgraded Apr 04
New major risk - Revenue and earnings growth Apr 01
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 31
INmune Bio, Inc. to Report Q4, 2023 Results on Mar 28, 2024 Mar 27
INmune Bio, Inc. Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro Mar 08
Inmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’S Disease Program Jan 31
New minor risk - Share price stability Jan 30
Is INmune Bio (NASDAQ:INMB) Using Debt Sensibly? Jan 19
INmune Bio, Inc. Provides Update Regarding Global Alzheimer's Phase Ii Clinical Trial and Clinical Hold Issued by the United States FDA Dec 19
Inmune Bio Inc. Demonstrates That INB03 Enhances the Uptake of Trastuzumab Deruxtecan in Her2+ Breast Cancer with Muc4 Expression in Poster Presented At San Antonio Breast Cancer Symposium Nov 30
INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease Nov 29
INmune Bio, Inc. Receives EMA's Authorization in France and Spain for Phase II Clinical Trial of XPro for Early Alzheimer's Disease Nov 28
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer's Disease in Europe Nov 17
Consensus revenue estimates increase by 30%, EPS downgraded Nov 08
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 03
Inmune Bio, Inc. Announces Update Regarding Patent Claims Covering Inb16 Cell Line Nov 01
INmune Bio, Inc. Presents New Biomarker and Feasibility Data from Phase 1b Study Supporting the Use of XPro™ to Treat Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease Conference Oct 18
INmune Bio, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 17
Inmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’S Disease Sep 06
Is INmune Bio (NASDAQ:INMB) Using Debt In A Risky Way? Sep 04
Consensus revenue estimates increase by 51% Aug 14
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 08
INmune Bio, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Aug 01 INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease
INmune Bio, Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology Jul 11
Is INmune Bio (NASDAQ:INMB) Using Too Much Debt? May 12
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer May 09
First quarter 2023 earnings released: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022) May 04
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 03
INmune Bio, Inc. Announces Pre-Clinical Data to Support Pioneering Approach to Treating Duchenne Muscular Dystrophy Jan 26
Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money Jan 16
INmune Bio, Inc. Reports Combination Therapy with INB03™ Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 Expressing HER2+ Breast Cancer Dec 08
Insufficient new directors Dec 02 INmune Bio, Inc. Focuses on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments Nov 30
Price target decreased to US$14.33 Nov 16
Inmune Bio, Inc. Receives Health Canada “No Objection Letter” to Commence Clinical Trial of Xpro1595 in Mild Alzheimer’S Disease Nov 15
Consensus revenue estimates increase by 24% Nov 09
Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.55 loss in 3Q 2021) Nov 04
INmune Bio, Inc. to Report Q3, 2022 Results on Nov 02, 2022 Oct 27
INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune Oct 20
Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.44 loss in 2Q 2021) Aug 05
Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money Jul 11
CFO, Treasurer & Secretary recently bought US$69k worth of stock Jun 01
INmune Bio: Possibly The Once In A Lifetime Dip May 25
INmune Bio, Inc. Provides Additional Manufacturing Information to FDA as Part of IND Application for XPro1595™ in Alzheimer’s Disease May 24
Inmune Bio, Inc. Presents Data Demonstrating Xpro™ Promotes Remyelination in Gray Matter At 3rd European Conference on Neuroinflammation May 12
Price target decreased to US$22.33 Apr 27
INmune Bio, Inc., Annual General Meeting, Jun 01, 2022 Apr 20
INmune Bio, Inc. Announces Dosing of First Patient Enrolled in its Phase 2 Trial Using XPro1595 (XPro™) to Treat Neuroinflammation as Cause of Alzheimer’s Disease Apr 14
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research Annual Meeting 2022 Apr 12
INmune Bio, Inc. Highlights INKmune™ Data Featured in NK Cells in Solid Tumors Workshop at Innate Killer Summit Apr 06
INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors Apr 05
Is INmune Bio (NASDAQ:INMB) A Risky Investment? Mar 25
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 05 Shareholder Returns INMB US Biotechs US Market 7D 1.6% -3.3% -0.4% 1Y -60.8% -2.7% 24.8%
See full shareholder returns
Return vs Industry: INMB underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: INMB underperformed the US Market which returned 24.8% over the past year.
Price Volatility Is INMB's price volatile compared to industry and market? INMB volatility INMB Average Weekly Movement 9.7% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: INMB has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INMB's weekly volatility (10%) has been stable over the past year.
About the Company INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company’s development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers.
Show more INmune Bio, Inc. Fundamentals Summary How do INmune Bio's earnings and revenue compare to its market cap? INMB fundamental statistics Market cap US$99.55m Earnings (TTM ) -US$41.27m Revenue (TTM ) US$42.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) INMB income statement (TTM ) Revenue US$42.00k Cost of Revenue US$0 Gross Profit US$42.00k Other Expenses US$41.31m Earnings -US$41.27m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.86 Gross Margin 100.00% Net Profit Margin -98,266.67% Debt/Equity Ratio 6.4%
How did INMB perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 01:11 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources INmune Bio, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners Joel Beatty Baird Mayank Mamtani B. Riley Securities, Inc.
Show 6 more analysts 
